Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Real-time Estimate Cboe BZX  -  12:22 2022-11-30 pm EST
2.115 USD   -3.42%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

07/05/2022 | 07:25am EST

Adagio Therapeutics, Inc. announced that David Hering,M.B.A., age 47 who has been serving as the company's interim chief executive officer and chief operating officer, has been named permanent CEO. Mr. Hering served as the Company's Interim Chief Executive Officer from February 2022 until the Effective Date, and as Chief Operating Officer from June 2021 until the Effective Date. Prior to joining the Company, Mr. Hering served as the Head of the mRNA Global Franchise Business of Pfizer, Inc., a pharmaceutical company, from April 2021 to June 2021, the President of North America Vaccines of Pfizer, Inc. from December 2018 to April 2021 and the Vaccines Commercial Officer of Pfizer, Inc. from June 2015 to December 2018.

Before joining Pfizer in 2015, Mr. Hering spent seven years at Novartis Vaccines, a pharmaceutical company, where he held the position of Head of the North America Region. Mr. Hering received an M.B.A. from Harvard Business School and a B.S. in Operations Research and Industrial Engineering from Cornell University.


ę S&P Capital IQ 2022
All news about INVIVYD, INC.
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Develo..
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
GL
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
CI
11/10INVIVYD, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Transcript : Invivyd, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GL
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -236 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -1,01x
Yield 2022 -
Capitalization 239 M 239 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 2,19 $
Average target price 3,83 $
Spread / Average Target 75,0%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.-69.83%239
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.05%31 776
GENMAB A/S20.91%28 866